We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

268 hedge funds and large institutions have $5.5B invested in Array Biopharma Inc in 2019 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 101 increasing their positions, 75 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

338% more call options, than puts

Call options by funds: $89.5M | Put options by funds: $20.4M

114% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 29

83% more capital invested

Capital invested by funds: $3B → $5.5B (+$2.5B)

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

35% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 75

14% more funds holding

Funds holding: 236 → 268 (+32)

Holders
268
Holders Change
+32
Holders Change %
+13.56%
% of All Funds
5.8%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.28%
New
62
Increased
101
Reduced
75
Closed
29
Calls
$89.5M
Puts
$20.4M
Net Calls
+$69.1M
Net Calls Change
+$50.4M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$123M
2
PA
Perceptive Advisors
New York
+$88M
3
MWNA
Marshall Wace North America
New York
+$52.9M
4
ACA
Avoro Capital Advisors
New York
+$41.6M
5
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$33.4M

Top Sellers

1
RG
Redmile Group
California
-$114M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84M
3
Millennium Management
Millennium Management
New York
-$30.8M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$30.7M
5
BI
BVF Inc
California
-$27.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
VEA
151
Virtus ETF Advisers
New York
$1.19M +$217K +10,443 +27%
BG
152
Bellevue Group
Switzerland
$1.18M +$1M +48,200 New
Squarepoint
153
Squarepoint
New York
$1.14M +$13.8K +663 +1%
Mirae Asset Global Investments
154
Mirae Asset Global Investments
South Korea
$1.12M +$956K +45,918 New
BC
155
Brinker Capital
Pennsylvania
$1.11M +$376K +18,063 +66%
IA
156
IFG Advisory
Georgia
$1.01M -$2.31K -111 -0.3%
HI
157
HBK Investments
Texas
$982K +$838K +40,262 New
AG
158
Aperio Group
California
$967K +$127K +6,096 +18%
Commonwealth Equity Services
159
Commonwealth Equity Services
Massachusetts
$965K +$82.2K +3,950 +11%
SIM
160
Sonora Investment Management
Arizona
$930K -$28.6K -1,375 -3%
NSAM
161
North Star Asset Management
Wisconsin
$917K – – –
DCM
162
Dupont Capital Management
Delaware
$896K – – –
XK
163
Xact Kapitalforvaltning
Sweden
$884K – – –
NICM
164
Neo Ivy Capital Management
New York
$862K +$737K +35,381 New
PVAM
165
Pacific View Asset Management
California
$854K -$2.33M -111,908 -76%
BPB
166
Badgley, Phelps & Bell
Washington
$841K – – –
Creative Planning
167
Creative Planning
Kansas
$826K +$6.25K +300 +0.9%
USAA
168
United Services Automobile Association
Texas
$819K +$34.6K +1,662 +5%
PI
169
PEAK6 Investments
Illinois
$806K +$688K +33,042 New
SBH
170
Segall Bryant & Hamill
Illinois
$805K -$281K -13,485 -29%
Public Employees Retirement Association of Colorado
171
Public Employees Retirement Association of Colorado
Colorado
$804K – – –
PPCM
172
Pillar Pacific Capital Management
California
$765K -$18.7K -900 -3%
AB
173
Amalgamated Bank
New York
$764K +$28.5K +1,371 +5%
WCM Investment Management
174
WCM Investment Management
California
$759K +$648K +31,140 New
MAM
175
Meeder Asset Management
Ohio
$732K +$582K +27,972 +1,334%
5 6
7
8 9

ARRY Hedge Fund Activity: Q1 2019 in Review

268 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2019, worth a combined $5.5B — up 83% from $3B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new ARRY positions and 29 closed out — a net gain of 33 holders — while 101 added to existing stakes and 75 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was Redmile Group, cutting an estimated $114M.

  • 268 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2019, up from 236 in Q4 2018.
  • Funds reported $5.5B of Array Biopharma Inc stock for Q1 2019, up 83% quarter-over-quarter.
  • 62 funds opened new Array Biopharma Inc positions in Q1 2019 and 29 closed out, a net change of +33 holders.
  • The largest Array Biopharma Inc buyer in Q1 2019 was T. Rowe Price Associates, an estimated $123M added.
  • The largest Array Biopharma Inc seller in Q1 2019 was Redmile Group, an estimated $114M sold.

Based on aggregated 13F filings for Q1 2019.